Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
NASDAQ:BCLI
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.33Last Year’s EPS
0.6Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 16, 2025
|% Change Since: -6.90%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in regulatory clearance and clinical trial preparations for NurOwn, alongside promising biomarker research and development in the exosome program. However, financial constraints and the need for funding to initiate the trial were notable challenges.Company Guidance
During the Brainstorm Cell Therapeutics First Quarter 2025 Conference Call, extensive guidance was provided regarding the company's strategic and operational plans. The company announced the U.S. FDA clearance to initiate a pivotal Phase 3b trial for their NurOwn technology, aimed at treating early-stage ALS patients, marking a significant regulatory milestone. Additionally, they plan to initiate manufacturing at the Tel Aviv Sourasky Medical Center, with a subsequent technology transfer to Pluri for expanded cleanroom facilities. The trial, named ENDURANCE, is designed under a Special Protocol Assessment (SPA) with the FDA to mitigate regulatory risks. Approximately 15 leading clinical centers across the U.S. are poised to participate in the trial, with ongoing negotiations for clinical trial agreements. The company also highlighted the financial constraints and ongoing efforts to secure strategic funding, including a $15 million non-dilutive grant under review. These initiatives underscore the company's commitment to developing innovative therapeutic options for ALS within a challenging financial environment.Regulatory Clearance for Phase 3b Trial
The U.S. FDA has cleared Brainstorm Cell Therapeutics to initiate the Phase 3b trial for NurOwn, marking a significant milestone in their ALS treatment development.
Strong Interest from Clinical Sites
Brainstorm is negotiating with approximately 15 leading clinical centers across the United States for their Phase 3b trial, highlighting strong interest and support from renowned ALS clinicians and researchers.
Positive Biomarker Research
Significant changes in biomarkers were observed in the study, showing NurOwn's potential multimodal mechanism of action, including neuroprotective and anti-inflammatory effects.
Exosome Program Progress
Promising preclinical data from Brainstorm's exosome program demonstrates therapeutic effects in models of lung disease, with active pursuit of strategic partnerships for clinical development.
BCLI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BCLI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 16, 2025 | $1.16 | $1.32 | +13.79% |
Mar 31, 2025 | $1.19 | $1.26 | +5.88% |
Nov 14, 2024 | $1.13 | $1.21 | +7.08% |
Aug 14, 2024 | $4.78 | $4.58 | -4.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Brainstorm Cell Therapeutics (BCLI) report earnings?
Brainstorm Cell Therapeutics (BCLI) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is Brainstorm Cell Therapeutics (BCLI) earnings time?
Brainstorm Cell Therapeutics (BCLI) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCLI EPS forecast?
BCLI EPS forecast for the fiscal quarter 2025 (Q2) is -0.33.